While at the Rodman & Renshaw’s 16th
Annual Conference in New York City today, we had the opportunity to listen in
on more than 60 different presentations. The companies below caught our
attention.
Celsion Corp. (NASDAQ: CLSN) is a
fully-integrated oncology company focused on developing a portfolio of
innovative cancer treatments, including directed chemotherapies,
immunotherapies and RNA- or DNA-based therapies. The company’s lead program is
ThermoDox®, a proprietary heat-activated liposomal encapsulation of
doxorubicin, currently in Phase III development for the treatment of primary
liver cancer. The pipeline also includes EGEN-001, a DNA-based immunotherapy
for the localized treatment of ovarian and brain cancers. For more information,
visit www.celsion.com.
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is
an oncology company developing new treatments for cancer and associated pain.
The company’s most advanced asset Cynviloq™, the next-generation paclitaxel,
commenced its registrational trial in March 2014 and is being developed under
the abbreviated 505(b)(2) regulatory pathway. Sorrento is also developing RTX,
a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the NIH to treat
terminal cancer patients suffering from intractable pain. For more information,
visit www.sorrentotherapeutics.com.
Solitario Exploration & Royalty Corp.
(NYSE MKT: XPL) is a gold, silver, platinum-palladium, and base metal
exploration and royalty company with projects in Brazil, Mexico, Peru and
Nevada. Success achieved thus far has been fueled by management’s ability to
identify large-potential early stage exploration properties and subsequently
leverage these successes into partnerships with senior mining companies. The
company currently has significant business relationships with Votorantim Metais
and Anglo Platinum. For more information, visit www.solitarioxr.com.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
